Drugs / Regulatory T cells
Regulatory T cells
Trials 8
News releases announcing trial results or a regulatory action · 77
| Date | Issuer | Release |
|---|---|---|
| 2026-08-26 | TRex Bio, Inc. | Results TRexBio Announces Positive Topline Results from First-in-Human Phase 1a Study of TRB-061, a TNFR2 Agonist in Clinical Development for Atopic Dermatitis trex.bio ↗
Unblinded single- and multiple-dose results in healthy participants showed consistent pharmacokinetics and reproducible activation and expansion of immunoregulatory Tregs, supporting proof of mechanism for TRB-061 |
| 2026-08-25 | Nektar Therapeutics | Results Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis nektar.com ↗ |
| 2026-06-11 | Purple Biotech Ltd. | Results Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window purple-biotech.com ↗
These effects were not observed with IM1340, the NKG2A loss-of-function variant, underscoring the essential and differentiated contribution of the NKG2A arm. |
| 2026-05-21 | Aulos Bioscience, Inc. | Results Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting aulosbio.com ↗
Durable increases in CD8+ T cells and CD8/Treg ratios were observed in patients, with a corresponding decrease in Tregs. |
| 2026-05-14 | Apexigen America, Inc. | Results Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones pyxisoncology.com ↗
Treatment with maMICVO reduced the overall abundance of immune-suppressive regulatory T cells (Tregs) in MOC2 tumors, increased the CD8 T cell-to-Treg ratio and enhanced the abundance of a progenitor exhausted T cell subset that is highly responsive to anti-PD-1 therapy. |
| 2026-04-17 | Apexigen America, Inc. | Results Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026 pyxisoncology.com ↗
Treatment with maMICVO reduced the overall abundance of immune-suppressive regulatory T cells (Tregs) in MOC2 tumors |
| 2026-02-20 | NeoImmuneTech | Results NeoImmuneTech-Enabled “Expand & Pull” Immunotherapy Strategy for Glioblastoma Published in Nature Communications neoimmunetech.com ↗
Specifically, intratumoral CD8 T cells increased, while immunosuppressive regulatory T cells (Tregs) decreased, shifting the tumor microenvironment toward a more immune-responsive state. |
| 2026-02-11 | PolTREG S.A. | Regulatory PolTREG moves forward with the European registration process for Treg therapy in type 1 diabetes poltreg.bio ↗
The European Medicines Agency (EMA) has officially qualified PolTREG to submit an application for marketing authorization in the European Union for the PolTREG-T1D cell preparation. |
| 2026-01-05 | Coherus Oncology, Inc. | Results Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) coherus.com ↗
The findings show that the antibody, now named tagmokitug, demonstrated no off-target binding, and selectively eliminates CCR8+ T regulatory cells and not other T cells, supporting its potential as an anticancer treatment. |
| 2025-11-27 | PolTREG S.A. | Results PolTREG published data in a prestigious scientific journal demonstrating the long-term effectiveness of TREG cell therapy, which can halt the development of type 1 diabetes in children poltreg.bio ↗
Long-term effectiveness and safety have been confirmed by data published in the prestigious journal Diabetes, Obesity and Metabolism. |
| 2025-11-12 | Parvus Therapeutics, Inc. | Results Parvus Therapeutics Reports Positive Phase 1 Results for Lead Autoimmune Treg Therapy, PVT201 parvustx.com ↗
Importantly, post-dose increases in the expression of pre-selected markers exclusively on antigen-specific T-cells provided clear evidence of in vivo differentiation of antigen-specific autoreactive T-cells into Treg cells. |
| 2025-11-07 | Coherus Oncology, Inc. | Results Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody coherus.com ↗
In on-treatment tumor biopsies, CHS‑114 depleted CCR8+ Tregs, but not CCR8- Tregs, and increased CD8+ T cells in the tumor microenvironment (TME), indicating TME remodeling for antitumor immune activation and establishing proof of mechanism. |
| 2025-11-07 | Aulos Bioscience, Inc. | Results New Phase 2 Data for Aulos Bioscience’s Imneskibart Reveal Clinical Activity in Melanoma and Non-Small Cell Lung Cancer aulosbio.com ↗
The data also reinforce that a persistent reduction in regulatory T cells (Tregs) coupled with a higher CD8/Treg ratio is associated with longer overall survival (OS), progression-free survival (PFS) and time on treatment for patients. |
| 2025-10-29 | Sonoma Biotherapeutics, Inc. | Results Sonoma Biotherapeutics Announces Positive Interim Safety and Efficacy Data from Phase 1 REGULATE-RA Study of SBT-77-7101 in Refractory Rheumatoid Arthritis sonomabio.com ↗ |
| 2025-06-24 | Nektar Therapeutics | Results REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis nektar.com ↗
Across all three dose arms, translational blood biomarker data demonstrate robust on-target and dose-dependent pharmacological activity with an increase in total Tregs of up to 6-fold in the high dose arm. |
| 2025-05-06 | Tiziana Life Sciences LTD | Results Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis tizianalifesciences.com ↗
Single-cell RNA sequencing revealed early and sustained changes in peripheral immune cells, including increased regulatory T cells (Tregs) and expression of TGFβ across multiple cell types. |
| 2025-04-29 | Aulos Bioscience, Inc. | Results Aulos Bioscience Presents New Phase 2 Data for AU-007 Demonstrating Continued Strong Anti-Tumor Activity in Advanced Cancers at AACR Annual Meeting aulosbio.com ↗
AU-007’s unique clinical activity includes CD8 effector T cell expansion, corresponding Treg reduction and correlated increases in progression-free survival |
| 2025-04-28 | Tempest Therapeutics | Results Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting tempesttx.com ↗
The data presented at the AACR Annual Meeting show that amezalpat reduced tumor promoting immunosuppression by M2 macrophages and T regulatory cells resulting in immune activation. |
| 2025-04-28 | Coherus Oncology, Inc. | Results Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 coherus.com ↗
The data showed a confirmed partial response in a heavily pretreated PD-1 refractory patient, a > 50% depletion in CCR8+ Treg, and an increase in CD8+ T cells, consistent with anti-tumor activity and demonstrating proof of mechanism. |
| 2025-03-28 | Chugai Pharmaceutical | Results Joint Research Results on Regulatory T cells between Osaka University Immunology Frontier Research Center and Chugai Published in Nature chugai-pharm.co.jp ↗
This study is the first to elucidate the regulatory network of FoxP3, a master transcription factor essential for maintaining Treg function, in human induced regulatory T cells (iTreg), and proposes the possibility of new autoimmune disease treatment through Treg regulation. |
| 2025-02-27 | Tiziana Life Sciences LTD | Results Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury tizianalifesciences.com ↗
The publication revealed that nasal anti-CD3 therapy induces IL-10 producing regulatory T cells (Tregs) that migrate to the brain and modulate microglia activity. |
| 2024-11-25 | Medicenna Therapeutics, Inc. | Results Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO) medicenna.com ↗
Bizaxofusp is designed to target both the tumor and the TME, by selectively killing IL4R-expressing cancer cells, immune suppressive myeloid-derived suppressor cells (MDSCs) and Tregs. |
| 2024-11-07 | Aulos Bioscience, Inc. | Results Strong Evidence of AU-007’s Anti-Tumor Activity in Advanced Solid Tumor Cancers Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting aulosbio.com ↗
Data from all 77 patients show durable reductions in immunosuppressive Treg cells – a result unprecedented in the IL-2 class – with a correlation between longer progression-free survival outcomes as Treg reduction deepens. |
| 2024-10-29 | Nektar Therapeutics | Results Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases nektar.com ↗
Results from the Phase 1b studies showed that rezpegaldesleukin safely and dose-dependently increased Tregs and rapidly improved measurable exploratory disease outcomes that are largely durable for at least 36 weeks after ceasing treatment. |
| 2024-10-22 | Quell Therapeutics Limited | Results Quell Therapeutics to Present Promising Data from Autologous and Allogenic CAR-Treg Programs at Upcoming International Congresses quell-tx.com ↗
The in vitro characterization data demonstrates the identity, stability and functionality of the iPSC-derived Tregs, which exhibit potent suppressive activity. |
| 2024-09-09 | PolTREG S.A. | Results PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence poltreg.bio ↗ |
| 2024-06-05 | Quell Therapeutics Limited | Results Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR- Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients quell-tx.com ↗
Infusion of QEL-001 was shown to be safe and well tolerated in the safety cohort (n=3) |
| 2024-05-23 | Coherus Oncology, Inc. | Results Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting coherus.com ↗ |
| 2024-04-15 | Regimmune Corporation | Results REGiMMUNE Announces the Poster Presentation at the AACR 2024 Annual Meeting for RGI-2001 Phase 2b latest analyses. regimmune.com ↗
A large percentage of activated Tregs were proliferating, with activated Tregs proliferating to a greater extent compared with nonactivated Tregs. |
| 2024-03-12 | Selecxine | Results rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors selecxine.com ↗
The TME is characterized by an increased infiltration of tumor-specific CD8+ T cells, and a decreased frequency of CD39highTIM-3+ Treg cells. |
| 2023-11-03 | Coherus Oncology, Inc. | Results Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC) coherus.com ↗
Anti-CCR8 antibody, CHS-114, depletes tumor-infiltrating Treg cells and activates NK cells in dissociated head and neck squamous cell carcinoma (HNSCC) tumors |
| 2023-10-31 | Citius Pharmaceuticals, Inc. | Results Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor citiuspharma.com ↗
Preclinical study demonstrates that adding LYMPHIR to anti-PD-1 treatment augments anti-tumor activity and improves overall survival compared to monotherapy alone by transiently depleting Tregs in the tumor microenvironment |
| 2023-05-30 | Xencor, Inc. | Results Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress xencor.com ↗
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced the presentation of results from its Phase 1a single-ascending dose study of XmAb ® 564 in healthy volunteers. |
| 2023-05-18 | Outpace Bio, Inc. | Results Outpace Bio to present new data on OutSmart™ IL-2/15, a CAR T cell-produced designed cytokine with tumor-localized immune cell activity, at the 2023 annual meeting of the American Society of Gene & Cell Therapy (ASGCT) outpacebio.com ↗
Our preclinical data demonstrate that designed OutSmart TM IL-2/15 cytokine preferentially stimulates CD8+ immune effector cells, including CD8+ T cells and NK cells, while minimizing the activation of immune suppressive regulatory T cells (Tregs). |
| 2023-05-18 | Orchard Therapeutics | Results Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications orchard-tx.com ↗
Data from transplanted mice show that the preferential expression of CAR in HSC-derived regulatory T cells in vivo does not significantly alter the development, phenotype or function of these suppressive immune cells. |
| 2023-05-09 | Parvus Therapeutics, Inc. | Results Parvus Therapeutics announces a publication describing the cellular origin of Treg cells generated endogenously by Navacim therapy. parvustx.com ↗ |
| 2023-04-19 | Revolo Biotherapeutics | Results Revolo Biotherapeutics Announces Positive Topline Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis revolobio.com ↗
Importantly, ‘1104 treated patients showed an increase in both Regulatory B cells (Bregs) and Regulatory T cells (Tregs) that act to suppress inflammatory immune responses. |
| 2023-04-17 | Bright Peak Therapeutics Inc | Results Bright Peak Presents New Data at AACR: BPT567 A First-in-Class Multifunctional αPD1-IL18 Immunocytokine brightpeaktx.com ↗
Marked expansion of CD8+ T-cells and reduction of regulatory T-cells, with mediation of tumor regression via CD8+ T-cell dependent mechanism(s) |
| 2023-04-04 | Tiziana Life Sciences LTD | Results Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference tizianalifesciences.com ↗
Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have beneficial effect in intracerebral hemorrhage |
| 2023-03-30 | Medicenna Therapeutics, Inc. | Results Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study medicenna.com ↗
Results showed MDNA11 stimulating the proliferation and activation of anti-cancer CD8+ T cells but not regulatory T cells (Tregs), which are associated with pro-tumor immune pathways. |
| 2022-11-07 | Xencor, Inc. | Results Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study xencor.com ↗ |
| 2022-11-07 | Xencor, Inc. | Results Xencor Reports Third Quarter 2022 Financial Results xencor.com ↗
The study demonstrated that a single dose of XmAb564 is well tolerated and generates durable, dose-dependent and selective expansion of Tregs. |
| 2022-10-11 | GentiBio, Inc | Results GentiBio Announces Preclinical Data Showing Antigen Specific Engineered Tregs Suppressing Pancreatic Inflammation and Potential Utility for Treatment and Prevention of Clinical Type 1 Diabetes (T1D) gentibio.com ↗
GentiBio and colleagues demonstrated the ability of EngTregs to specifically target pancreas cells and draining lymph nodes in order to mitigate destruction and inflammation associated with the development of T1D within the context of ongoing inflammation. |
| 2022-09-15 | GentiBio, Inc | Results GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases gentibio.com ↗
Tregs Potency, Survival and Engraftment Significantly Enhanced Through Delivery of Engineered Tregs with Tunable IL-2 Signaling Support |
| 2022-09-01 | Coya Therapeutics | Results Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in Amyotrophic Lateral Sclerosis (ALS) coyatherapeutics.com ↗
The majority (6 out of 8) of patients either slowed or stopped progression (mean change of -2.7 points on ALSFRS-R score) during the open label extension over a 24-week period while 2 out of 8 patients did not benefit from treatment |
| 2022-05-27 | iOnctura | Results iOnctura to present at ASCO IOA-244 showing highly promising impact on overall survival for patients with metastatic and refractory uveal melanoma ionctura.com ↗
Tregs reduced by IOA-244 in peripheral blood and tumor tissue, supporting mechanism of action |
| 2022-04-27 | Coya Therapeutics | Results Coya Therapeutics Announces Annals of Neurology Publication Featuring Biomarker Data in ALS Patients Treated with Tregs Cell Therapy coyatherapeutics.com ↗
Coya Therapeutics, Inc. (“Coya”), a privately held clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced the publication of results from a Phase 1 trial entitled “Tregs Attenuate Peripheral Oxidative Stress and Acute Phase Proteins in ALS.” |
| 2022-02-15 | Adlai Nortye Biopharma Co., Ltd. | Results Adlai Nortye Announces Publication of Preclinical Research of AN3025 (anti-hTNFR2）in Frontiers in Immunology adlainortye.com ↗
AN3025 treatment can reduce the proportion of regulatory T cells (Treg), increase the infiltration of effector CD4+ T cells and CD8+ T cells, and upregulate the expression of immune activation genes such as interferon-γ (IFN-γ) and granzyme K (Granzyme K) in the tumor microenvironment, leading to strong anti-tumor effects. |
| 2022-01-20 | Transgene | Results Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade transgene.com ↗ |
| 2021-11-04 | BioLineRx, Ltd. | Results BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition biolinerx.com ↗
The Company is also presenting findings from in-vivo and in-vitro pre-clinical studies demonstrating that Motixafortide acts as an immunomodulator by affecting the biology of regulatory T cells (Tregs), supporting biomarker findings from the Company's COMBAT Phase 2 study in pancreatic cancer patients. |
| 2021-10-19 | Quell Therapeutics Limited | Results Quell Therapeutics Presents New Data Demonstrating the Ability of its Proprietary Phenotype Lock Technology to Enhance the Safety, Stability and Efficacy of Engineered Treg Therapies quell-tx.com ↗
In addition, the enhanced expression of FOXP3 was also observed to improve the antigen-specific suppressive function of engineered CAR-Tregs. |
| 2021-07-07 | Coya Therapeutics | Regulatory Coya Therapeutics Receives Orphan Drug Designation from the FDA for ALS001, an Autologus Treg Cell Therapy, for the Treatment of ALS coyatherapeutics.com ↗ |
| 2021-05-20 | Nektar Therapeutics | Results Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity nektar.com ↗
These published data demonstrate that NKTR-358 has the ability to elicit sustained and preferential proliferation and activation of Tregs in vivo without corresponding increases in T effector cells. |
| 2021-02-04 | Regimmune Corporation | Results REGiMMUNE presented at the ASH annual meeting on 5 December 2020 regimmune.com ↗
Increases of % of Tregs/CD4 + T cells may have potential in prevention of acute GVHD. |
| 2021-01-20 | Faron Pharmaceuticals Ltd | Results Bexmarilimab (Clevegen) development update faron.com ↗
Never during my career have I seen that a high baseline count of regulatory T cells (Tregs) predicts a good response to a therapy. |
| 2020-11-04 | Nektar Therapeutics | Results New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress nektar.com ↗
Complementing these clinical results, we also observed dose-dependent biomarker changes associated with Treg activation including increases in Treg functional markers, changes in DNA methylation of the FoxP3 locus, and increased expression of Treg functional genes, |
| 2020-06-22 | MacroGenics | Results MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting macrogenics.com ↗
Separately, we are presenting data from our novel Fc-engineered, bispecific DART® molecule that binds CD25 and CTLA-4 that is capable of depleting tumor-infiltrating regulatory T cells with high specificity in vitro, |
| 2020-06-04 | Nektar Therapeutics | Results Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020) nektar.com ↗
show that NKTR-358 was safe and well tolerated in patients with mild-to-moderate SLE and led to a marked and selective, dose-dependent expansion of regulatory T cells (Tregs) that was maintained over multiple administrations. |
| 2020-04-14 | Invion, Inc. | Results Preliminary data links Photosoft with immune response inviongroup.com ↗
An increased ratio of Teff-to-Treg cells observed in PhotosoftTM treated mice in an ovarian cancer model parallels similar changes typically associated with improved survival and treatment outcomes in ovarian cancer patients |
| 2020-03-25 | Medicenna Therapeutics, Inc. | Results Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study medicenna.com ↗
This allows MDNA19 to specifically activate naïve CD8 T cells and natural killer (NK) cells with minimal stimulation of T regulatory cells (Tregs), thereby circumventing toxicity and demonstrating potential for best-in-class features. |
| 2019-11-19 | Selecxine | Results TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity selecxine.com ↗
Among them, the hIL-2/TCB2 complex (hIL-2/TCB2c) exerted the best efficacy by inducing a prodigious expansion of host memory phenotype (MP) CD8 T (60-fold) and NK cells (18-fold) with less efficient Treg proliferation (5-fold). |
| 2019-11-08 | Alkermes, Inc. | Results Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting alkermes.com ↗
Consistent with earlier non-clinical findings, treatment with ALKS 4230 selectively expanded natural killer (NK) and CD8+ T cells and had negligible, non-dose-dependent effects on regulatory T cells (Tregs). |
| 2019-10-24 | VBI Vaccines Inc. | Results VBI Vaccines to Present New Immuno-Oncology Data at the World Vaccine Congress Europe 2019 vbivaccines.com ↗
In Part A, three out of the six (3/6) patients in the high-dose cohort had evidence of stable disease by magnetic resonance imaging (MRI), which correlated with vaccine-induced T-cell responses. |
| 2019-09-30 | Medicenna Therapeutics, Inc. | Results Medicenna Presented Promising Preclinical Results from its IL-2 Superkine Platform at the 5th Annual International Cancer Immunotherapy Conference medicenna.com ↗
High potency towards naïve effector T cells but diminished potency on unwanted regulatory T cells (Tregs). |
| 2019-09-26 | Medicenna Therapeutics, Inc. | Results Nature Communications Publishes Studies on Medicenna's IL-2 Superkine Platform medicenna.com ↗
It has increased half-life and preferentially boosts tumor killing CD8+ T cells instead of tumor protecting regulatory T cells (Tregs). |
| 2019-06-13 | Nektar Therapeutics | Results First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology nektar.com ↗
The data presented at EULAR 2019 demonstrate its meaningful and targeted effect of selective proliferation of Treg cells, |
| 2019-02-21 | Actinium Pharmaceuticals | Results Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy actiniumpharma.com ↗
Tregs or regulatory T cells, including CD4+, CD25+ and FoxP3+ Tregs, which can exert negative pressure on cell therapy expansion and persistence, were suppressed for at least 21 days post lymphodepletion with Iomab-ACT. |
| 2018-11-06 | Alkermes, Inc. | Results Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting alkermes.com ↗
Consistent with the known biological activities of IL-2, administration of high-dose IL-2 resulted in an approximate 2-fold expansion of circulating cytotoxic effector CD8+ T cells and NK cells and an approximate 4-fold expansion of circulating Treg cells. |
| 2018-03-22 | BioInvent International AB | Results BioInvent researchers co-publish article in Cancer Cell on mechanism of action of anti-CTLA-4 antibodies bioinvent.com ↗
researchers from University College in London publish translational data demonstrating that the activity of clinically validated anti-CTLA-4 antibodies depends, at least in part, on the depletion of tumour-infiltrating Treg cells. |
| 2018-01-26 | Verastem, Inc. | Results Verastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination with Immune Checkpoint or Co-Stimulatory Antibodies in B Cell Lymphoma Model verastem.com ↗
When duvelisib and anti-OX40 were combined, tumor regression was observed which correlated with strong reduction of tumor Tregs, M2 macrophages and myeloid-derived suppressor cells. |
| 2018-01-17 | BioLineRx, Ltd. | Results BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer biolinerx.com ↗
BL-8040 also induced an increase in the number of total immune cells in the peripheral blood, while the frequency of peripheral blood regulatory T cells (Tregs), known to impede the anti-tumor immune response, was decreased. |
| 2017-06-08 | CEL-SCI Corporation | Results CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal cel-sci.com ↗
The authors concluded that CEL-4000 exerts its therapeutic effect by interacting with CD4+ cells, which results in an antigen-specific down-modulation of pathogenic CD4+ cell responses through up modulation of CD4+ FoxP3+ Treg cells. |
| 2017-05-04 | Alligator Bioscience AB | Results Alligator Bioscience presents promising immuno-oncology data at US conference; – Strong new preclinical findings for ADC-1013 and ATOR-1015 alligatorbioscience.se ↗
ATOR-1015 activated effector T-cells and suppressed regulatory T-cells in tumors, but not elsewhere in the body. |
| 2016-12-05 | Omeros Corporation | Results Omeros’ Proprietary Orphan GPCR Program Delivers New Target and Approach in Cancer Immunotherapy omeros.com ↗
Moreover, GPR174 inhibition statistically significantly reduced by approximately 40 percent the population of Tregs, a subset of T-cells elevated in a large number of cancers. |
| 2015-08-03 | Protalix | Results Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results for PRX-106 Oral Anti-TNF protalix.com ↗
Regulatory T cell activation showing biological activity in the gut was observed. |
| 2015-04-22 | argenx | Results arGEN-X Announces Publication on Therapeutic Potential of ARGX-115 in Cancer Immunotherapy argenx.com ↗
This monoclonal antibody is the first therapeutic agent to show an inhibitory activity on the immunosuppressive function of human Tregs. |
| 2010-04-30 | Regimmune Corporation | Results REGiMMUNE Presents New ToleroVax Data at the 2010 American Transplant Congress regimmune.com ↗
The study found that the combination of the two drugs showed a robust synergy and induced proliferation in more than 70% of regulatory T cells (Tregs), a T cell subset that plays a central role in inducing and maintaining immune tolerance. |
All press releases naming this drug 83 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Regulatory T Cells | “Patients received an infusion of 2 × 106/kg donor regulatory T cells on day -4 followed by 1 × 106/kg donor conventional T cells on day -1 and a mean of 10.7 × 106 ± 3.4 ×...” PMID 33646302 ↗ Mar 2021 |
| Known as | Treg | “Regulatory T-Cells (Treg)” NCT01660607 ↗ |
| Known as | Tregs | “The patient received a single infusion of 1×106 autologous, ex vivo expanded, polyclonal Tregs per kilogram of body weight, and the clinical, biochemical, endoscopic and...” PMID 35428657 ↗ Apr 2022 |
| Modality | Cell therapy | “These are the enriched but naturally-occurring regulatory T cells.” NCT01050764 ↗ |
| Route | Other | “Regulatory t cells will be injected back to autoimmune hepatitis patients” NCT02704338 ↗ |